TNB-486 induces potent tumor cell cytotoxicity coupled with low cytokine release in preclinical models of B-NHL
Harbani K. Malik-Chaudhry, Kirthana Prabhakar, Harshad S. Ugamraj, Andrew Boudreau, Benjamin Buelow, Kevin Dang, Laura Davison, Katherine E. Harris, Brett Jorgensen, Heather Ogana, Duy Pham, Ute Schellenberger, Wim van Schooten, Roland Buelow, Suhasini Iyer, Nathan D. Trinklein, Udaya S. Rangaswamy
Abstract
, TNB-486 clears CD19+ tumor cells in immunocompromised mice in the presence of human peripheral blood mononuclear cells in multiple models. Additionally, the PK of TNB-486 in mice or cynomolgus monkeys is similar to conventional antibodies. This new T cell engaging bispecific antibody targeting CD19 represents a novel therapeutic that induces potent T cell-mediated tumor-cell cytotoxicity uncoupled from high levels of cytokine release, making it an attractive candidate for B-NHL therapy.